natgillin/translations-raw huggingface dataset:
Blood glucose (mmol/ l)
Po subkutani injekciji je delovanje zdravila NovoRapid kratkotrajnejše kot delovanje topnega humanega insulina. glukoza v krvi (mmol/ l
Time (h) Fig.
čas (ure) Slika I.
Blood glucose concentrations following a single pre-meal dose of NovoRapid injected immediately before a meal (solid curve) or soluble human insulin administered 30 minutes before a meal (hatched curve) in patients with type 1 diabetes mellitus.
Koncentracija glukoze v krvi po enem odmerku zdravila NovoRapid, injiciranem tik pred obrokom (neprekinjena krivulja) in topnega humanega insulina, apliciranega 30 minut pred obrokom (pikčasta krivulja) pri bolnikih z diabetesom mellitusom tipa 1.
When NovoRapid is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection.
NovoRapid začne delovati v 10 do 20 minutah po subkutani injekciji.
6 Adults.
6 Odrasli.
I).
Klinična preskušanja pri bolnikih z diabetesom tipa 1 so pokazala, da je postprandialna koncentracija glukoze v krvi po zdravilu NovoRapid nižja kot po topnem humanem insulinu (slika I).
In two long-term open label trials in patients with type 1 diabetes comprising 1070 and 884 patients, respectively, NovoRapid reduced glycosylated haemoglobin by 0.12 [95% C. I.
V dveh dolgoročnih, odprtih preskušanjih pri bolnikih z diabetesom tipa 1, ki sta vključili 1070 oz.
0.03; 0.22] percentage points and by 0.15 [95% C. I.
884 bolnikov, je NovoRapid v primerjavi s humanim insulinom znižal glikiran hemoglobin za 0, 12 [95% interval zaupanja 0, 03; 0, 22] oz.
0.05; 0.26] percentage points compared to human insulin; a difference of doubtful clinical significance.
0, 15 [95% interval zaupanja 0, 05; 0, 26] odstotnih točk; klinični pomen razlike je dvomljiv.
Elderly.
Starejši.
A randomised, double-blind cross-over PK/ PD trial comparing insulin aspart with soluble human insulin was performed in elderly patients with type 2 diabetes (19 patients aged 65-83 years, mean age 70 years).
Pri starejših bolnikih z diabetesom tipa 2 (19 bolnikov, starih od 65 do 83 let, povprečna starost 70 let) so opravili randomizirano, dvojno slepo navzkrižno preskušanje farmakokinetike/ farmakodinamike, med katerim so insulin aspart primerjali s topnim humanim insulinom.
The relative differences in the pharmacodynamic properties (GIRmax, AUCGIR, 0- 120 min) between insulin aspart and human insulin in elderly were similar to those seen in healthy subjects and in younger subjects with diabetes.
Relativne razlike v farmakodinamičnih lastnostih (GIRmax, AUCGIR, 0- 120 min) insulina aspart in humanega insulina so se pri starejših skladale s tistimi, ki so bile ugotovljene pri zdravih preiskovancih in mlajših osebah z diabetesom.
Children and adolescents.
Otroci in mladostniki.
A clinical trial comparing preprandial soluble human insulin with postprandial insulin aspart was performed in small children (20 patients aged 2 to less than 6 years, studied for 12 weeks, among those four were younger than 4 years old) and a single dose PK/ PD trial was performed in children (6-12 years) and adolescents (13-17 years).
Izvedli so klinično raziskavo, v kateri so primerjali topni humani insulin apliciran pred obrokom z insulinom aspart apliciranim po obroku pri majhnih otrocih (20 bolnikih starih med 2 in manj kot 6 let, od katerih so bili štirje mlajši od 4 let; v raziskavi so bili 12 tednov) in raziskavo farmakokinetike/ farmakodinamike enkratnega odmerka pri otrocih (starih 6 do 12 let) in mladostnikih (starih 13 do 17 let).
Clinical trials in patients with type 1 diabetes have demonstrated a reduced risk of nocturnal hypoglycaemia with insulin aspart compared with soluble human insulin.
Klinična preskušanja pri bolnikih z diabetesom tipa 1 so pokazala, da je tveganje za nočno hipoglikemijo po insulinu aspart manjše kot po topnem humanem insulinu.
The risk of daytime hypoglycaemia was not significantly increased.
Tveganje za hipoglikemijo čez dan se ni značilno zvečalo.
165)) did not indicate any adverse effect of insulin aspart on pregnancy or on the health of the foetus/ newborn.
Klinično preskušanje, v katerem so primerjali varnost in učinkovitost insulina aspart in humanega insulina v zdravljenju nosečnic z diabetesom tipa 1 (322 izpostavljenih nosečnosti (insulin aspart 157, humani insulin 165)), ni pokazalo nobenih neželenih učinkov insulina aspart na nosečnost ali na zdravje ploda/ novorojenčka.
13) showed similar safety profiles between treatments.
Poleg tega so podatki kliničnega preskušanja, ki je zajelo 27 žensk z gestacijskim diabetesom, randomiziranih na zdravljenje z insulinom aspart ali humanim insulinom (insulin aspart 14, humani insulin 13), pokazali podobna profila varnosti obeh terapij.
NovoRapid is therefore more rapidly absorbed from the subcutaneous layer compared to soluble human insulin.
Substitucija aminokisline prolina z asparaginsko kislino na položaju B28 v zdravilu NovoRapid zmanjša nagnjenost k tvorbi heksamer, ki je opazna pri topnem humanem insulinu. Zato se NovoRapid v primerjavi s topnim humanim insulinom hitreje absorbira iz podkožja.
A mean maximum plasma concentration of 492±256 pmol/ l was reached 40 (interquartile range:
Povprečna največja koncentracija v plazmi 492 ± 256 pmol/ l je bila pri bolnikih z diabetesom tipa 1 dosežena v 40 (interkvartilni razpon:
30– 40) minutes after a subcutaneous dose of 0.15 U/ kg bodyweight in type 1 diabetic patients.
30– 40) minutah po subkutanem odmerku 0, 15 e. / kg telesne mase.
The absorption rate was somewhat slower in type 2 diabetic patients, resulting in a lower Cmax (352±240 pmol/ l) and later tmax (60 (interquartile range:
Pri bolnikih z diabetesom tipa 2 je bila hitrost absorpcije nekoliko počasnejša, zato je bila Cmax manjša (352 ± 240 pmol/ l), tmax pa poznejši (60 (interkvartilni razpon:
50– 90) minutes).
50– 90) minut).
The pharmacokinetic and pharmacodynamic properties of NovoRapid were investigated in children (6– 12 years) and adolescents (13– 17 years) with type 1 diabetes.
Farmakokinetične in farmakodinamične lastnosti zdravila NovoRapid so raziskali pri otrocih (6– 12 let) in mladostnikih (13– 17 let) z diabetesom tipa 1.
Elderly:
7 Starejši:
A decreased absorption
Relativne razlike v farmakokinetičnih lastnostih med insulinom aspart in topnim humanim insulinom so bile pri starejših preiskovancih (65– 83 let, povprečna starost 70 let) z diabetesom tipa 2 podobne kot pri zdravih preiskovancih in pri mlajših osebah z diabetesom.
7 rate was observed in elderly subjects, resulting in a later tmax (82 (interquartile range:
Pri starejših preiskovancih je bila hitrost absorpcije nižja, zato je bil tmax daljši (82 (interkvartilni razpon:
60-120) minutes), whereas Cmax was similar to that observed in younger subjects with type 2 diabetes and slightly lower than in subjects with type 1 diabetes.
60- 120) minut), medtem ko je bila Cmax podobna kot pri mlajših osebah z diabetesom tipa 2 in rahlo nižja kot pri osebah z diabetesom tipa 1.
In subjects with hepatic impairment absorption rate was decreased and more variable, resulting in delayed tmax from about 50 min in subjects with normal hepatic function to about 85 min in subjects with moderate and severe hepatic impairment.
Pri bolnikih z okvaro jeter je bila hitrost absorpcije nižja in bolj spremenljiva, zato je bil tmax daljši in se je gibal v razponu od 50 minut pri preiskovancih z normalnim delovanjem jeter do 85 minut pri preiskovancih z zmerno in hudo okvaro jeter.
AUC, Cmax and CL/ F were similar in subjects with reduced hepatic function compared with subjects with normal hepatic function.
AUC, Cmax in očistek (CL/ F) so bili pri preiskovancih z zmanjšanim delovanjem jeter podobni tistim pri preiskovancih z normalnim delovanjem jeter.
No apparent effect of creatinine clearance values on AUC, Cmax, CL/ F and tmax of insulin aspart was found.
Ugotovili niso nobenega očitnega vpliva očistka kreatinina na AUC, Cmax, očistek (CL/ F) in tmax insulina aspart.
Data were limited in subjects with moderate and severe renal impairment.
Pri bolnikih z zmerno in hudo okvaro ledvic so bili podatki omejeni.
Subjects with renal failure necessitating dialysis treatment were not investigated.
Farmakokinetike pri bolnikih z odpovedjo ledvic, ki potrebujejo zdravljenje z dializo, niso raziskali.
In in vitro tests, including binding to insulin and IGF-1 receptor sites and effects on cell growth, insulin aspart behaved in a manner that closely resembled human insulin.
V preskusih in vitro, vključno z vezavo na receptorska mesta za insulin in IGF- 1 ter učinki na celično rast, se je insulin aspart obnašal zelo podobno humanemu insulinu.
Glycerol Phenol Metacresol Zinc chloride Disodium phosphate dihydrate Sodium chloride Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections
glicerol fenol metakrezol cinkov klorid natrijev hidrogenfosfat dihidrat natrijev klorid klorovodikova kislina (za uravnavo pH) natrijev hidroksid (za uravnavo pH) voda za injekcije
Substances added to the insulin may cause degradation of the insulin, e. g. if the medicinal product contains thiol or sulphites.
Insulinu dodane snovi lahko povzročijo razgradnjo insulina, npr. če dodano zdravilo vsebuje tiole ali sulfite.
The in-use shelf life is 4 weeks.
Rok uporabnosti med uporabo je 4 tedne.
Store in a refrigerator (2°C – 8°C).
Shranjujte v hladilniku (pri temperaturi med 2 °C in 8 °C)!
Keep the vial in the outer carton in order to protect from light.
Za zagotovitev zaščite pred svetlobo shranjujte vialo v zunanji ovojnini!
Do not refrigerate.
Vial, ki so v uporabi ali jih imate pri sebi za rezervo, ne shranjujte v hladilniku!
Glass vial (Type 1) closed with a disc (bromobutyl/ polyisoprene rubber) and a protective tamper-proof plastic cap containing 10 ml of solution.
Viala vsebuje 10 ml raztopine.
Cartons of 1 or 5 vials and a multipack with 5 x (1 x 10 ml) vials.
Škatlice z 1 ali 5 vialami in skupno pakiranje 5 x (1 x 10 ml) vial.
NovoRapid vials are for use with insulin syringes with the corresponding unit scale.
Viale NovoRapid so namenjene uporabi z insulinskimi brizgami, ki imajo ustrezno odmerno skalo.
NovoRapid may be used in an infusion pump system (CSII) as described in section 4.2.
NovoRapid se lahko uporablja v infuzijskem sistemu s črpalko (CSII), kot je opisano v poglavju 4. 2.
Tubings in which the inner surface materials are made of polyethylene or polyolefin have been evaluated and found compatible with pump use.
Cevke, ki imajo notranjo površino iz polietilena ali poliolefina, so ocenili in ugotovili, da se lahko uporabljajo s črpalko.
For intravenous use, infusion systems with NovoRapid 100 U/ ml at concentrations from 0.05 U/ ml to 1.0 U/ ml insulin aspart in the infusion fluids 0.9% sodium chloride, 5% dextrose or 10% dextrose inclusive 40 mmol/ l potassium chloride using polypropylene infusion bags are stable at room temperature for 24 hours.
Infuzijski sistemi za intravensko infundiranje z zdravilom NovoRapid 100 e. / ml v koncentraciji od 0, 05 do 1, 0 e. / ml insulina aspart v infuzijskih tekočinah 0, 9% raztopine natrijevega klorida, 5% raztopine glukoze ali 10% raztopine glukoze, vključno s 40 mmol/ l raztopine kalijevega klorida, z uporabo polipropilenskih infuzijskih vrečk so pri sobni temperaturi stabilni 24 ur.
Monitoring of blood glucose is necessary during insulin infusion.
Med infundiranjem insulina je treba kontrolirati glukozo v krvi.
NovoRapid should not be used if it does not appear clear and colourless.
Zdravila NovoRapid se ne sme uporabiti, če ni bister in brezbarven.
7 September 1999 Date of last renewal:
7. september 1999 Datum zadnjega podaljšanja dovoljenja za promet:
NovoRapid Penfill 100 U/ ml, solution for injection in a cartridge.
NovoRapid Penfill 100 e. / ml raztopina za injiciranje v injekcijskem vložku
Insulin aspart∗.......................................... .100 U/ ml
100 e. / ml
In a meal-related treatment 50– 70% of this requirement may be provided by NovoRapid and the remainder by intermediate-acting or long-acting insulin.
V okviru zdravljenja, povezanega s prehrano, lahko 50– 70% te potrebe pokrije NovoRapid Penfill, preostanek pa srednjedolgodelujoč ali dolgodelujoč insulin.
NovoRapid is administered subcutaneously in the abdominal wall, the thigh, the deltoid region or the gluteal region.
NovoRapid se aplicira subkutano z injiciranjem v trebušno steno, stegno, deltoidni predel ali glutealni predel.
10 If necessary, NovoRapid may also be administered intravenously (see section 6.6) which should be carried out by health care professionals.
10 Če je potrebno, je mogoče NovoRapid aplicirati tudi intravensko (glejte poglavje 6. 6), vendar ga sme tako aplicirati samo zdravnik.
NovoRapid may be used for Continuous Subcutaneous Insulin Infusion (CSII) in pump systems suitable for insulin infusion.
NovoRapid se lahko uporablja za kontinuirano subkutano infundiranje insulina (CSII – Continuous Subcutaneus Insulin Infusion) v sistemih s črpalko, primernih za infundiranje insulina.
The use of dosages which are inadequate or discontinuation of treatment, especially in insulin- dependent diabetics, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal.
Neustrezno odmerjanje ali prekinitev zdravljenja, posebno pri diabetesu, odvisnem od insulina, lahko vodi v hiperglikemijo in diabetično ketoacidozo; stanji, ki sta lahko smrtni.
Changes in strength, brand, type, species (animal, human, human insulin analogue) and/ or method of manufacture may result in a change in dosage.
Spremembe v jakosti, znamki, vrsti, izvoru (živalski, humani, analog humanega insulina) in/ ali načinu izdelave insulina, imajo lahko za posledico spremembo odmerjanja.
Patients taking NovoRapid may require an
Bolniki, ki uporabljajo NovoRapid, utegnejo potrebovati večje število dnevnih injekcij ali drugačen odmerek kot med
11 increased number of daily injections or a change in dosage from that used with their usual insulins.
11 uporabo svojih običajnih insulinov.
As with any insulin, injection site reactions may occur and include pain, itching, hives, swelling and inflammation.
Kot pri vsakem insulinu se lahko pojavijo reakcije na mestu injiciranja, vključno z bolečinami, srbenjem, koprivnico, oteklino in vnetjem.
12 hypoglycaemia or have frequent episodes of hypoglycaemia.
To je posebno pomembno pri bolnikih z zmanjšanim ali odsotnim zaznavanjem opozorilnih znakov hipoglikemije in pri tistih, ki imajo pogoste hipoglikemije.
4.8 Undesirable effects
12 4. 8 Neželeni učinki
Uncommon (> 1/ 1,000 ,< 1/100) and rare (> 1/10 ,000, < 1/1,000).
Pogostnosti so opredeljene kot: občasno (> 1/ 1. 000, < 1/ 100) in redko (> 1/ 10. 000, < 1/ 1. 000).
Uncommon - Diabetic retinopathy Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Diabetična retinopatija – občasno Dolgoročno izboljšana urejenost glikemije zmanjša tveganje za napredovanje diabetične retinopatije.
13 4.9 Overdose
13 4. 9 Preveliko odmerjanje
In two long-term open label trials in patients with type 1 diabetes comprising 1070 and 884 patients, respectively, NovoRapid reduced glycosylated haemoglobin by 0.12 [95% C. I.
14 V dveh dolgoročnih, odprtih preskušanjih pri bolnikih z diabetesom tipa 1, ki sta vključili 1070 oz.
NovoRapid is therefore more rapidly absorbed from the subcutaneous layer compared to soluble human insulin.
Zato se NovoRapid v primerjavi s topnim humanim insulinom hitreje absorbira iz podkožja.
The pharmacokinetic and pharmacodynamic properties of NovoRapid were investigated in children (6– 12 years) and adolescents (13– 17 years) with type 1 diabetes.
Farmakokinetične in farmakodinamične lastnosti NovoRapida so raziskali pri otrocih (6– 12 let) in mladostnikih (13– 17 let) z diabetesom tipa 1.
However, Cmax differed between the age groups, stressing the importance of the individual titration of NovoRapid
Cmax pa se je med starostnima skupinama razlikovala, kar poudarja pomembnost individualnega titriranja NovoRapida.
The relative differences in pharmacokinetic properties between insulin aspart and soluble human insulin in elderly subjects (65-83 years, mean age 70 years) with type 2 diabetes were similar to those observed in healthy subjects and in younger subjects with diabetes.
Relativne razlike v farmakokinetičnih lastnostih med insulinom aspart in topnim humanim insulinom so bile pri starejših preiskovancih (65– 83 let, povprečna starost 70 let) z diabetesom tipa 2 podobne kot pri zdravih preiskovancih in pri mlajših osebah z diabetesom.
A decreased absorption
60- 120) minut), medtem
60-120) minutes), whereas Cmax was similar to that observed in younger subjects with type 2 diabetes and slightly lower than in subjects with type 1 diabetes.
15 ko je bila Cmax podobna kot pri mlajših osebah z diabetesom tipa 2 in rahlo nižja kot pri osebah z diabetesom tipa 1.
Store in a refrigerator (2°C – 8°C).
Shranjujte v hladilniku (med 2 °C in 8 °C)!
Keep the cartridge in the outer carton in order to protect from light.
Za zagotovitev zaščite pred svetlobo shranjujte vialo v zunanji ovojnini!
16 NovoRapid Penfill in use or carried as a spare:
16 Vložki NovoRapid Penfill, ki so v uporabi ali jih ima bolnik pri sebi za rezervo:
A glass (Type 1) cartridge which contains a piston (bromobutyl rubber) and is closed with a disc (bromobutyl/ polyisoprene rubber) containing 3 ml of solution.
Vložek vsebuje 3 ml raztopine.
Cartons of 5 or 10 cartridges.
Škatlice s 5 ali 10 vložki.
NovoRapid Penfill should only be used in combination with products that are compatible with them and allow the Penfill to function safely and effectively.
Vložke NovoRapid Penfill se sme uporabljati samo z izdelki, s katerimi so kompatibilni in ki omogočajo varno in učinkovito delovanje teh vložkov.
NovoRapid Penfill is for use by one person only.
NovoRapid Penfill je namenjen uporabi ene same osebe.
NovoRapid Penfill is designed to be used with the Novo Nordisk insulin delivery system and NovoFine needles.
NovoRapid Penfill je namenjen za uporabo z aplikacijskimi sistemi Novo Nordisk in iglami NovoFine.
NovoRapid NovoLet 100 U/ ml, solution for injection in a pre-filled pen.
NovoRapid NovoLet 100 e. / ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Due to the faster onset of action, NovoRapid should generally be given immediately before a meal.
NovoRapid začne delovati hitreje in deluje krajši čas kot topni humani insulin. Zaradi hitrejšega začetka delovanja je treba NovoRapid praviloma aplicirati tik pred obrokom.
As with all insulins the duration of action will vary according to the dose, injection site, blood flow, temperature and the level of physical activity.
Tako kot pri vseh insulinih je trajanje delovanja spremenljivo, odvisno od odmerka, mesta injiciranja, krvnega pretoka, temperature in stopnje telesne dejavnosti.
18 If necessary, NovoRapid may also be administered intravenously (see section 6.6) which should be carried out by health care professionals.
19 Če je potrebno, je mogoče NovoRapid aplicirati tudi intravensko (glejte poglavje 6. 6), vendar ga sme tako uporabiti samo zdravnik.
19 increased number of daily injections or a change in dosage from that used with their usual insulins.
20 uporabo svojih običajnih insulinov.
20 hypoglycaemia or have frequent episodes of hypoglycaemia.
To je posebno pomembno pri bolnikih z zmanjšanim ali odsotnim zaznavanjem opozorilnih znakov hipoglikemije in pri tistih, ki imajo pogoste hipoglikemije.
Very rare - Anaphylactic reactions Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.
Zelo redko – anafilaktične reakcije Med simptomi generalizirane preobčutljivosti so lahko generaliziran izpuščaj na koži, srbenje, znojenje, prebavne motnje, angionevrotični edem, težko dihanje, palpitacije in znižanje krvnega tlaka.
Skin and subcutaneous tissue disorders Uncommon - Lipodystrophy Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.
Bolezni kože in podkožja Občasno - lipodistrofija Če bolnik mest injiciranjna posameznem predelu ne menja krožno, se lahko pojavi lipodistrofija.
21 4.9 Overdose
22 4. 9 Preveliko odmerjanje
A specific overdose for insulin cannot be defined however hypoglycaemia may develop over sequential stages if too high doses relative to the patient’ s requirement are administered:
Specifičnega prevelikega odmerjanja insulina ni mogoče opredeliti, a če so uporabljeni odmerki preveliki glede na bolnikovo potrebo, se lahko v zaporednih stopnjah razvije hipoglikemija: • Blage hipoglikemije je mogoče zdraviti z zaužitjem glukoze ali sladkih izdelkov, zato naj ima sladkorni bolnik vedno pri sebi nekaj živil, ki vsebujejo sladkor. • Hude hipoglikemije, ko je bolnik nezavesten, je mogoče zdraviti z glukagonom (0, 5 do 1 mg), ki ga intramuskularno ali subkutano aplicira ustrezno podučena oseba, ali z glukozo, ki jo intravensko aplicira zdravstveni delavec.
22 Adults.
Odrasli.
0.03; 0.22] percentage points and by 0.15 [95% C. I.
23 884 bolnikov, je NovoRapid v primerjavi s humanim insulinom znižal glikirani hemoglobin za 0, 12 [95% interval zaupanja 0, 03; 0, 22] oz.
However, Cmax differed between the age groups, stressing the importance of the individual titration of NovoRapid Elderly:
Cmax pa se je med starostnima skupinama razlikovala, kar poudarja pomembnost individualnega titriranja zdravila NovoRapid.
A decreased absorption rate was observed in elderly subjects, resulting in a later tmax (82 (interquartile range:
Pri starejših preiskovancih je bila hitrost absorpcije nižja, zato je bil tmax daljši (82 (interkvartilni razpon:
60-120)
60- 120) minut), medtem
23 minutes), whereas Cmax was similar to that observed in younger subjects with type 2 diabetes and slightly lower than in subjects with type 1 diabetes.
24 ko je bila Cmax podobna kot pri mlajših osebah z diabetesom tipa 2 in rahlo nižja kot pri osebah z diabetesom tipa 1.
Keep the cap on when NovoRapid Novolet is not in use in order to protect from light.
Kadar NovoRapid NovoLet ni v uporabi, naj bo za zaščito pred svetlobo pokrit s pokrovčkom!
NovoRapid NovoLet in use or carried as a spare:
25 NovoRapid NovoLet, ki je v uporabi ali ga ima bolnik pri sebi za rezervo:
24 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
A glass (Type 1) cartridge which contains a piston (bromobutyl rubber) and is closed with a disc (bromobutyl/ polyisoprene rubber) containing 3 ml of solution in a multidose disposable pre-filled pen with a pen injector (plastic).
Vložek iz stekla (tipa 1) z batom (iz bromobutilne gume), zaprt s ploščico (iz bromobutilne/ poliizoprenske gume) vsebuje 3 ml raztopine in je vstavljen v večodmeren napolnjen injekcijski peresnik s peresnim injektorjem (iz plastike), ki se po končani uporabi zavrže.
Cartons of 5 or 10 pre-filled pens.
Škatlice s 5 ali 10 napolnjenimi injekcijskimi peresniki.
NovoRapid NovoLet should only be used in combination with products that are compatible with them and allow the pens to function safely and effectively.
Peresnike NovoRapid NovoLet se sme uporabljati samo z izdelki, s katerimi so kompatibilni in ki omogočajo varno in učinkovito delovanje teh peresnikov.
NovoRapid NovoLet is for use by one person only.
NovoRapid NovoLet je namenjen uporabi ene same osebe.
NovoRapid NovoLet must not be refilled.
Peresnikov NovoRapid NovoLet se ne sme znova polniti.
NovoFine needles are designed to be used with NovoRapid NovoLet.
Za uporabo s peresnikom NovoRapid NovoLet so namenjene igle NovoFine.
NovoRapid FlexPen 100 U/ ml, solution for injection in a pre-filled pen.
NovoRapid FlexPen 100 e. / ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Insulin aspart∗...........................................
Insulin aspart∗...........................................
The individual insulin requirement in adults and children is usually between 0.5 and 1.0 U/ kg/ day.
Individualna potreba po insulinupri odraslih in otrocih je ponavadi od 0, 5 do 1, 0 e. / kg/ dan.